Department of Ophthalmology, Vanderbilt University, Nashville, Tennessee 37232, USA.
Surv Ophthalmol. 2010 Mar-Apr;55(2):108-33. doi: 10.1016/j.survophthal.2009.07.005.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly employed in ophthalmology to reduce miosis and inflammation, manage scleritis, and prevent and treat cystoid macular edema associated with cataract surgery. In addition, they may decrease postoperative pain and photophobia associated with refractive surgery and may reduce the itching associated with allergic conjunctivitis. In recent years, the U.S. Food and Drug Administration has approved new topical NSAIDs, and previously approved NSAIDs have been reformulated. These additions and changes result in different pharmacokinetics and dosing intervals, which may offer therapeutic advantages. For example, therapeutic effects on diabetic retinopathy and age-related macular degeneration may now be achievable. We provide an updated review on NSAIDs and a summary of their current uses in ophthalmology with attention to potential future applications.
非甾体类抗炎药（NSAIDs）在眼科领域的应用日益广泛，可用于缩瞳和抗炎，治疗巩膜炎，并预防和治疗白内障手术后的囊样黄斑水肿。此外，它们还可以减轻屈光手术相关的术后疼痛和畏光，以及减轻过敏性结膜炎相关的瘙痒。近年来，美国食品和药物管理局（FDA）批准了新的局部用 NSAIDs，且之前批准的 NSAIDs 也进行了重新配方。这些新增和改变导致了不同的药代动力学和给药间隔，可能带来治疗优势。例如，现在可能可以实现对糖尿病视网膜病变和年龄相关性黄斑变性的治疗效果。我们提供了 NSAIDs 的最新综述，并概述了它们在眼科领域的当前用途，同时关注了潜在的未来应用。
